Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|February 23, 2022
Novavax Begins Shipping its COVID-19 Vaccine to European Union Member States
Author(s)Pharmaceutical Technology Editors
Novavax announces the first doses of Nuvaxovid COVID-19 vaccine have begun shipping to European Union member states.
Advertisement
Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced on Feb. 23, 2022 that the first doses of its Nuvaxovid COVID-19 vaccine have begun shipping to European Union (EU) member states. Nuvaxovid is the first protein-based COVID-19 vaccine authorized for use in Europe.
Nuvaxovid doses are shipping from Novavax’ Netherlands distribution center to EU member states. The first wave of shipments includes several countries, such as Germany, France, and Austria, with shipments to additional EU member states to quickly follow.
The European Commission (EC) granted conditional marketing authorization (CMA) for Nuvaxovid to prevent COVID-19 caused by SARS-Cov-2 in individuals 18 years of age or older. The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended authorization of the vaccine in all 27 EU member states in
"Today's announcement paves the way for vaccination with Nuvaxovid to begin in Europe within the coming days. The Novavax COVID-19 vaccine provides a differentiated option to bolster vaccination rates across Europe," said Stanley C. Erck, president and CEO of Novavax, in the press release. "Nuvaxovid has demonstrated efficacy, a reassuring safety and tolerability profile, and is built on a well-understood protein-based vaccine platform used for other vaccines for decades."
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement